Status:

COMPLETED

A Single Centre Open Label Comparison of [I-123]-Ortho-Iodohippuric Acid (OIH) With [Tc-99m]-Mercaptoacetyltriglycine (MAG3) for Assessment of Renal Tubular Function

Lead Sponsor:

Centre for Probe Development and Commercialization

Collaborating Sponsors:

McMaster University

St. Joseph's Healthcare Hamilton

Conditions:

Renal Function Impairment

Eligibility:

All Genders

18+ years

Brief Summary

Iodine-123 labelled ortho-Iodohippuric Acid (\[I-123\]-OIH) was used in the early 1970's as a kidney imaging agent or tracer that "lights-up" inside your body when scanned, but over the years its use ...

Detailed Description

This study is being conducted to compare two imaging agents (tracers): \[I-123\]-OIH and \[Tc-99m\]-MAG3 using gamma camera imaging in participants with different levels of kidney function. Gamma came...

Eligibility Criteria

Inclusion

  • At least 18 years of age.
  • Provide signed informed consent.
  • Documented stable renal impairment with an eGFR \< 60/mL/min/1.73m\^2 by two eGFR measurements within 3 months that are within ± 15% of each other or healthy prospective kidney donor with an eGFR ≥ 60 mL/min/1.73m\^2.

Exclusion

  • Females who are pregnant, planning to become pregnant or are lactating.
  • Clinically relevant abnormal findings that could, in the opinion of the investigator, interfere with the safe completion of the study.
  • Unable, in the opinion of the clinician or investigator, to tolerate fluid intake required for radionuclide renography.
  • Participation in any clinical trial involving an investigational product within 30 days prior to the first injection.
  • Not using an adequate method of family planning unless the participant, or the male participant's partner, has had a hysterectomy, a tubal ligation, is postmenopausal or is not at risk of pregnancy.
  • Unable to lie still in a supine position for at least 30 minutes.
  • Unable to complete study procedures, including follow-up safety assessments.
  • Medical or psychological conditions that on assessment by the principal investigator make the participant unable to complete the procedure.
  • History of allergic reaction to iodine or iodine compounds, inclusive of iodinated x-ray contrast media.
  • Any other conditions that may impact the participant's ability to complete the study.

Key Trial Info

Start Date :

September 1 2012

Trial Type :

OBSERVATIONAL

Allocation :

ACTUAL

End Date :

April 1 2014

Estimated Enrollment :

6 Patients enrolled

Trial Details

Trial ID

NCT01496391

Start Date

September 1 2012

End Date

April 1 2014

Last Update

April 9 2014

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

St. Joesph's Healthcare Hamilton

Hamilton, Ontario, Canada, L8N 4A6